



# **Recommendations for Testing, Managing, and Treating Hepatitis C**

Downloaded from <http://www.hcvguidelines.org>

Visit the HCV Guidance website to access the most up-to-date version

Updated: July 6, 2016. Changes made July 8, 2016.

## **cirrhosis.**

Rating: Class I, Level B

\*The dose of daclatasvir may need to increase or decrease when used concomitantly with cytochrome P450 3A/4 inducers and inhibitors, respectively. Please refer to the prescribing information and the section on [HIV/HCV coinfection](#) for patients on antiretroviral therapy.

### **Genotype 1b Treatment-Naïve Patients with [Compensated Cirrhosis](#)<sup>‡</sup> - Recommended**

*Recommended regimens are listed in groups by level of evidence, then alphabetically.*

- **Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for 12 weeks is a Recommended regimen for treatment-naïve patients with HCV genotype 1b infection who have [compensated cirrhosis](#).**  
Rating: Class I, Level A
- **Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks is a Recommended regimen for treatment-naïve patients with HCV genotype 1b infection who have [compensated cirrhosis](#).**  
Rating: Class I, Level A
- **Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) for 12 weeks is a Recommended regimen for treatment-naïve patients with HCV genotype 1b infection who have [compensated cirrhosis](#).<sup>†</sup>**  
Rating: Class I, Level A
- **Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for 12 weeks is a Recommended regimen for treatment-naïve patients with HCV genotype 1b infection who have [compensated cirrhosis](#).**  
Rating: Class I, Level A

<sup>‡</sup> [For decompensated cirrhosis, please refer to the appropriate section.](#)

<sup>†</sup> Please see statement on FDA [warning](#) regarding the use of PrOD or PrO in patients with cirrhosis.

### **Genotype 1b Treatment-Naïve Patients with [Compensated Cirrhosis](#)<sup>‡</sup> - Alternative**

*Alternative regimens are listed in groups by level of evidence, then alphabetically.*

- **Daily daclatasvir (60 mg\*) plus sofosbuvir (400 mg) with or without weight-based ribavirin for 24 weeks is an Alternative regimen for treatment-naïve patients with HCV genotype 1b infection who have [compensated cirrhosis](#).**  
Rating: Class IIa, Level B
- **Daily simeprevir (150 mg) plus sofosbuvir (400 mg) with or without weight-based ribavirin**